Last reviewed · How we verify
Buffered Anesthetic
Buffered Anesthetic, marketed by University Hospitals Cleveland Medical Center, holds a niche position in the anesthetic market with its unique formulation. The drug's key strength lies in its buffered composition, which may offer improved patient comfort and faster onset of action compared to non-buffered alternatives. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Buffered Anesthetic |
|---|---|
| Sponsor | University Hospitals Cleveland Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Split Face Study of the Duration of Local Anesthetics - Fourth Arm (PHASE4)
- Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT (PHASE4)
- Comparative Evaluation of the Effect of pH Adjustment of the Solution of Articaine With Epinephrine on the Efficacy of Jet Anesthesia (NA)
- Stellate Ganglion Block for PTSD (NA)
- TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer (NA)
- aDjunct bicarbonatE in Local anaesthesIa for CarpAl Tunnel rElease (DELICATE) (NA)
- Evaluate Buffering Local Anesthetic in Inflamed Teeth (NA)
- Wide-Awake Local Anesthesia No Tourniquet (WALANT) With Versus Without Hyaluronidase for Hand Surgery (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |